Özet:

Purpose: This clinical study includes a retrospective study of 138 patients using new oral anticoagulant drugs (rivaroksaban, dabigatran, apiksaban, edoksaban) due to deep venous thrombosis. The demographic characteristics of patients and the relationship of the disease, the start-end periods of treatment, radiological and clinical healing conditions, the side effects of new oral anticoagulants have been evaluated. Method: The retrospective study included 138 patients using new oral anticoagulant drugs. The demographic characteristics of patients, diagnosis and treatment schemes, radiological images, epicrisis notes were recorded. The records of each patient were monitored for 12 months. New oral anticoagulant effectiveness was assessed by measuring pre- and post-treatment swelling and bladder diamonds, whether there is rekanalization in doppler USG (rekanalization>75%), rekanalization time, bleeding side effects and healing times with treatment, recurrence rates. The data was studied statistically using the statistical program. Results: A significant difference was found when compared the average of the measurements of the diameter of the spine (Ort±SS:75,41 ) and the average of the diameter of the spine (Ort±SS:54,63) after treatment. by p<05. A significant difference was found when compared with the average measurements of the headache diameter (Ort±SS:43,99) and the average measurement of the headache diameter after treatment. by p<05. In patients after treatment, the full rekanalization rate of doppler USG was 54% (75 patients) in the 3rd month and 25% (35 patients) in the 6th month. The result: New oral anticoagulants (rivaroxaban, dabigatran, apiksaban, edoxaban) are very effective in the treatment of deep venous thrombosis of the lower limb, both in the provision of rekanalization and in the clinical sense of recovery. Side effects have been observed in an acceptable and compatible with literature.

Özet:

Objective: This clinical study included a retrospective evaluation of 138 patients using new oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) for lower extremity deep vein thrombosis. The demographic characteristics of the patients and the relationship between the disease, treatment initiation and end times, radiological and clinical recovery, and NOACSSS side effects were evaluated. Materials and Method: 138 patients using new oral anticoagulant drugs were included in the retrospective study. Demographic characteristics, diagnosis and treatment charts, radiological images, epicrisis notes of the patients were recorded. Records of each patient were reviewed during their 12 months of follow-up. New oral anticoagulant efficacy; It was evaluated by measuring thigh and calf diameters before and after treatment, whether there was recanalization in Doppler USG (recanalization> 75%), recanalization time, bleeding side effects and recovery times with treatment, and recurrence rates. The data were analyzed statistically using a statistics program. Results: A significant difference was found when the mean thigh diameter measurements measured at the beginning of the treatment (Mean ± SD: 75,41) and the mean thigh diameter measured after the treatment (Mean ± SD: 54,63) were compared. P <0.05. A significant difference was found when the mean calf diameter measurements (Mean ± SD: 43.99) measured at the beginning of the treatment and the mean calf diameter measured after the treatment were compared. P <0.05. Post-treatment Doppler USG showed complete recanalization rate in 54% (75 patients) at 3 months and 25% (35 patients) at 6 months. At the end of the 6th month, the total recanalization rate occurred in 80% (110) patients. Conclusion: New oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) are very effective in the treatment of lower extremity deep venous thrombosis, both in providing recanalization and in terms of clinical improvement. There were acceptable side effects in accordance with the literature.

Anahtar Kelimeler: